🇺🇸 FDA
Patent

US 11850243

Dihydropyridine compositions and methods for treating neurological disorders

granted A61KA61K31/4439A61P

Quick answer

US patent 11850243 (Dihydropyridine compositions and methods for treating neurological disorders) held by Cavalon Therapeutics, Inc. expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cavalon Therapeutics, Inc.
Grant date
Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/4439, A61P, A61P25/16